• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by McKesson Corporation

    5/30/25 10:03:49 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care
    Get the next $MCK alert in real time by email
    SD 1 mck_sdxcy2024.htm SD Document

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM SD
    Specialized Disclosure Report
    mckessonlogoa04a.jpg
    McKESSON CORPORATION
    (Exact Name of Registrant as Specified in Charter)

    Delaware1-1325294-3207296
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
    6555 State Hwy 161
    Irving, TX 75039
    (Address of Principal Executive Offices, and Zip Code)

    Michele Lau
    Executive Vice President and
    Chief Legal Officer
    (972) 446-4800
    (Name and telephone number,
    including area code, of the person
    to contact in connection with this report.)
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    x
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    o
    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended __________.
     
     



    Section 1    Conflict Minerals Disclosure

    Item 1.01     Conflict Minerals Disclosure and Report

    This Specialized Disclosure Report on Form SD (the “Form SD”) of McKesson Corporation (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934 for the reporting period January 1, 2024 to December 31, 2024. The Rule requires disclosure of certain information when a company manufactures or contracts to manufacture products for which the minerals specified in the Rule are necessary to the functionality or production of those products. The minerals specified in the rule are gold, columbite-tantalite (coltan), cassiterite and wolframite, including their derivatives, which are limited to tantalum, tin and tungsten (collectively, the “Conflict Minerals”). As provided by applicable guidance from the U.S. Securities and Exchange Commission (the “SEC”) regarding the Rule, this disclosure does not address products that did not enter the stream of commerce in the calendar year ending December 31, 2024.

    The following disclosure, in response to the provisions of paragraphs (a) and (b) of Item 1.01 of Form SD, has been made in accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporation Finance of the SEC on April 7, 2017 (the “April 2017 Guidance”). As permitted under the April 2017 Guidance, this Form SD does not address Item 1.01(c) of Form SD.

    Conflict Minerals Disclosure

    Description of the Company’s Products

    This Form SD relates to products (i) for which Conflict Minerals are necessary to the functionality or production of that product; (ii) that were manufactured, or contracted to be manufactured, by the Company; and (iii) for which the manufacture was completed during 2024. These products (collectively the “Covered Products”) consist of the Company’s pharmacy automation products.

    Reasonable Country of Origin Inquiry

    The Company has, in good faith and after reasonable due diligence, conducted a reasonable country of origin inquiry (“RCOI”) to determine whether Conflict Minerals that are necessary to the functionality or production of its Covered Products originated in the Democratic Republic of the Congo (“DRC”) or the adjoining countries of Angola, Burundi, Central African Republic, Republic of Congo, Rwanda, South Sudan, Tanzania, Uganda and Zambia (the “Covered Countries”), or whether any of the Conflict Minerals may have been from recycled or scrap sources. A summary of the Company’s RCOI process follows:

    The Company’s supply chain with respect to the Covered Products is complex, and there are many third parties in the supply chain between the ultimate manufacturer of the Covered Products and the original sources of the Conflict Minerals. The Company does not purchase Conflict Minerals directly from mines, smelters or refiners. The Company must therefore rely on its suppliers to provide information regarding the origin of the Conflict Minerals that are necessary to the functionality or production of the Covered Products.

    As an initial step, each of the Company’s business units that manufacture or contract to manufacture Covered Products were asked to evaluate the Covered Products to determine if Conflict Minerals may have been present and potentially necessary to the production or functionality of the Covered Product. Following that evaluation, each business unit used a risk-based approach to create a list of suppliers that were likely to have provided products containing Conflict Minerals during the reporting year ended December 31, 2024.

    The Company's RCOI included an inquiry into its pharmacy automation suppliers. The responses to the Company’s inquiry can be grouped into the three categories identified below:

    (1)The supplier represented that its products do not contain Conflict Minerals from the Covered Countries.
    (2)The supplier represented that its products do contain Conflict Minerals, but the Conflict Minerals are sourced from a smelter or refiner that is conformant.
    (3)The supplier represented that its products do contain Conflict Minerals, but the supplier is unable to identify the source of the Conflict Minerals or the status of the smelters or refiners (if any).

    Based on this RCOI, the Company has reason to believe that certain of its necessary Conflict Minerals contained in some Covered Products may have originated in a Covered Country and are not from recycled or scrap sources.



    A copy of this Form SD, together with a copy of our Conflict Minerals Policy, can be found on our corporate website at www.McKesson.com. From the main web page, scroll to the footer at the bottom and click Corporate Governance under the Investors heading, then scroll to the Quick Links section of the page that opens and click on McKesson Conflict Minerals Policy and Disclosures. The Company’s website and any information accessible through the website are not incorporated by reference into this Form SD.

    Item 1.02    Exhibit

    None.

    Section 2    Resource Extraction Issuer Disclosure

    Item 2.01    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3    Exhibits

    Item 3.01    Exhibits

    None.




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    Date: May 30, 2025
     
    McKesson Corporation
    By:/s/ Michele Lau
     Michele Lau
     Executive Vice President and Chief Legal Officer

    Get the next $MCK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MCK

    DatePrice TargetRatingAnalyst
    12/4/2024$630.00Neutral
    Mizuho
    11/7/2024$531.00 → $688.00Neutral → Outperform
    Robert W. Baird
    9/24/2024$603.00 → $531.00Outperform → Neutral
    Robert W. Baird
    9/5/2024$670.00 → $665.00Outperform
    Leerink Partners
    8/8/2024$540.00 → $570.00Neutral
    Mizuho
    2/26/2024$600.00Outperform
    Leerink Partners
    1/3/2024$537.00Overweight
    Barclays
    12/14/2023$502.00Equal Weight
    Wells Fargo
    More analyst ratings

    $MCK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Controller & CAO Rutledge Napoleon B Jr sold $68,201 worth of shares (95 units at $717.91), decreasing direct ownership by 9% to 986 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      5/29/25 2:18:46 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP & Chief HR Officer Smith Leann B sold $244,807 worth of shares (341 units at $717.91), decreasing direct ownership by 11% to 2,800 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      5/29/25 2:18:28 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • EVP, Chief Strategy & BDO Rodgers Thomas L sold $366,134 worth of shares (510 units at $717.91), decreasing direct ownership by 9% to 5,435 units (SEC Form 4)

      4 - MCKESSON CORP (0000927653) (Issuer)

      5/29/25 2:18:12 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Leadership Updates

    Live Leadership Updates

    See more
    • McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

      Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

      8/26/24 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals
    • Gentherm Announces Dr. Ken Washington as New Independent Director

      NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

      10/2/23 8:00:00 AM ET
      $AMZN
      $F
      $MCK
      $MDT
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Other Pharmaceuticals

    $MCK
    SEC Filings

    See more
    • SEC Form 144 filed by McKesson Corporation

      144 - MCKESSON CORP (0000927653) (Subject)

      5/30/25 10:27:36 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

      8-K - MCKESSON CORP (0000927653) (Filer)

      5/30/25 10:15:08 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SD filed by McKesson Corporation

      SD - MCKESSON CORP (0000927653) (Filer)

      5/30/25 10:03:49 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho resumed coverage on McKesson with a new price target

      Mizuho resumed coverage of McKesson with a rating of Neutral and set a new price target of $630.00

      12/4/24 7:43:38 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded McKesson from Neutral to Outperform and set a new price target of $688.00 from $531.00 previously

      11/7/24 6:29:13 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded McKesson from Outperform to Neutral and set a new price target of $531.00 from $603.00 previously

      9/24/24 8:19:53 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/13/24 5:09:38 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      1/25/24 1:48:52 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by McKesson Corporation (Amendment)

      SC 13G/A - MCKESSON CORP (0000927653) (Subject)

      2/10/22 8:27:59 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care

    $MCK
    Financials

    Live finance-specific insights

    See more
    • McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results and Provides Fiscal 2026 Guidance; Announces Intent to Separate Medical-Surgical Solutions

      McKesson Corporation (NYSE:MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

      5/8/25 4:10:00 PM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Declares Quarterly Dividend

      The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read

      5/1/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care
    • McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC

      Announces fourth quarter and full year fiscal 2025 earnings release date McKesson Corporation (NYSE:MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. McKesson acquired an approximate 80% controlling interest in PRISM Vision Holdings, an ophthalmology and retina management services provider, for about $850 million. PRISM physicians will retain an approximate 20% interest. The acquisition enables McKesson to develop a leading retinal and ophthalmology platform and expand McKesson's differentiated value proposition, clinical services a

      4/2/25 8:00:00 AM ET
      $MCK
      Other Pharmaceuticals
      Health Care